Shire, New River receive approvable letter for ADHD compound
Shire Friday received tentative FDA approval to market its new attention-deficit hyperactivity disorder (ADHD) drug, lisdexamfetamine dimesylate (LDX).
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.